Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-06-06 07:00 |
Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
|
English | 112.5 KB | ||
| 2019-05-31 07:00 |
Innate Pharma annonce une publication dans Cell sur des anticorps multispecifiq…
|
French | 92.9 KB | ||
| 2019-05-31 07:00 |
Innate Pharma announces publication in Cell on innovative multifunctional NKp46…
|
English | 88.6 KB | ||
| 2019-05-23 07:00 |
Innate Pharma annonce une publication dans “Cell Reports” sur une nouvelle géné…
|
French | 91.8 KB | ||
| 2019-05-23 07:00 |
Outcome of Annual General Meeting of May 22, 2019
|
English | 70.2 KB | ||
| 2019-05-15 07:00 |
Innate Pharma First Quarter 2019 Report
|
English | 143.6 KB | ||
| 2019-05-15 07:00 |
Information financière du premier trimestre 2019
|
French | 172.3 KB | ||
| 2019-05-01 07:00 |
Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 201…
|
English | 78.9 KB | ||
| 2019-05-01 07:00 |
Innate Pharma annonce la tenue de son Assemblée Générale Annuelle le 22 mai 201…
|
French | 79.5 KB | ||
| 2019-04-24 07:00 |
Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 18 avril 2019
|
French | 97.7 KB | ||
| 2019-04-24 07:00 |
Number of shares and voting rights of Innate Pharma as at April 18, 2019
|
English | 96.6 KB | ||
| 2019-04-01 07:00 |
Innate Pharma à l’AACR 2019 : nouvelles données sur la prochaine génération d’i…
|
French | 127.9 KB | ||
| 2019-04-01 07:00 |
Innate Pharma highlights next generation of cancer immunotherapies at the Ameri…
|
English | 134.7 KB | ||
| 2019-03-20 07:00 |
Resultats annuels 2018 : accord majeur avec AstraZeneca appuyant la transition …
|
French | 275.1 KB | ||
| 2019-03-20 07:00 |
2018 financial results and business update: landmark deal with AstraZeneca to s…
|
English | 269.3 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
